LU91328I2 - Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé) - Google Patents

Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)

Info

Publication number
LU91328I2
LU91328I2 LU91328C LU91328C LU91328I2 LU 91328 I2 LU91328 I2 LU 91328I2 LU 91328 C LU91328 C LU 91328C LU 91328 C LU91328 C LU 91328C LU 91328 I2 LU91328 I2 LU 91328I2
Authority
LU
Luxembourg
Prior art keywords
ätypes
recombinant
adsorbed
human papillomavirus
papillomavirus vaccine
Prior art date
Application number
LU91328C
Other languages
English (en)
Other versions
LU91328I9 (fr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91328(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority to LU91328C priority Critical patent/LU91328I2/fr
Publication of LU91328I2 publication Critical patent/LU91328I2/fr
Publication of LU91328I9 publication Critical patent/LU91328I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91328C 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé) LU91328I2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (fr) 1999-03-26 2000-03-22 Vaccin contre le papillomavirus aux particules viro-induites desassemblees et reassemblees
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)

Publications (2)

Publication Number Publication Date
LU91328I2 true LU91328I2 (fr) 2007-05-14
LU91328I9 LU91328I9 (fr) 2019-03-01

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
LU91326C LU91326I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
LU91326C LU91326I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)

Country Status (19)

Country Link
US (2) US6245568B1 (fr)
EP (1) EP1165126B1 (fr)
JP (1) JP4594534B2 (fr)
KR (1) KR20020013516A (fr)
AR (1) AR023166A1 (fr)
AT (1) ATE339222T1 (fr)
AU (1) AU778937B2 (fr)
CA (1) CA2368391C (fr)
CY (4) CY1105779T1 (fr)
DE (4) DE122007000033I1 (fr)
DK (1) DK1165126T3 (fr)
ES (1) ES2270822T3 (fr)
FR (1) FR07C0026I2 (fr)
LT (1) LTC1165126I2 (fr)
LU (3) LU91327I2 (fr)
NL (3) NL300270I1 (fr)
PT (1) PT1165126E (fr)
SI (1) SI1165126T1 (fr)
WO (1) WO2000057906A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
ES2325053T3 (es) * 1999-12-09 2009-08-25 Medimmune, Llc Metodo in vitro para desensamblaje/reensamblaje de particulas similares a virus de papilomavirus (vlp).
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (fr) * 2002-02-14 2003-08-21 Novavax, Inc. Optimisation de sequences de genes de pseudo-particules virales chimeriques pour l'expression de cellules d'insectes
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
MY144492A (en) 2002-12-20 2011-09-30 Glaxosmithkline Biolog Sa Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1785433A4 (fr) * 2004-07-01 2008-10-01 Tokyo Inst Tech Construction ressemblant a une particule virale et procede servant a former celle-ci dans des conditions physiologiques
BRPI0607269A2 (pt) * 2005-01-25 2009-08-25 Wyeth Res Ireland Ltd protetores de cisalhamento para colheita por microfiltragem
WO2007011711A2 (fr) * 2005-07-14 2007-01-25 Mayo Foundation For Medical Education And Research Preparations a base du virus paramyxoviridae
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
WO2007027076A1 (fr) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formule de stabilisation de vaccins comprenant des antigenes vivants a utiliser dans des systemes de vaccination de masse
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
JP5916610B2 (ja) 2009-09-03 2016-05-11 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 直接的な化学的溶解のための方法および組成物
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013132452A2 (fr) 2012-03-09 2013-09-12 Pfizer Inc. Compositions de neisseria meningitidis et procédés associés
WO2013139744A1 (fr) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Procédé de vaccination contre le papillomavirus humain
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP2964665B1 (fr) 2013-03-08 2018-08-01 Pfizer Inc Polypeptides immunogènes de fusion
CA2923129C (fr) 2013-09-08 2020-06-09 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procedes associes
WO2016132294A1 (fr) 2015-02-19 2016-08-25 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EP3583206A1 (fr) 2017-02-17 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Production acellulaire efficace de vecteurs de transfert du gène du virus à papillomes
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841708D1 (de) * 1997-02-06 2010-07-22 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
PL336715A1 (en) 1997-04-08 2000-07-03 Merck & Co Inc Stabilised formulation of human papilloma virus
CA2295316C (fr) 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques

Also Published As

Publication number Publication date
FR07C0026I1 (fr) 2007-04-27
LU91327I2 (fr) 2007-05-14
NL300269I2 (nl) 2008-07-01
WO2000057906A1 (fr) 2000-10-05
CY2007009I2 (el) 2010-07-28
JP2002540167A (ja) 2002-11-26
CY2007010I2 (el) 2009-11-04
LU91326I2 (fr) 2007-05-14
NL300268I1 (nl) 2007-05-01
DK1165126T3 (da) 2007-01-08
DE60030698D1 (de) 2006-10-26
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
JP4594534B2 (ja) 2010-12-08
LTC1165126I2 (lt) 2020-04-27
NL300270I1 (nl) 2007-05-01
CY2007008I2 (el) 2009-11-04
EP1165126B1 (fr) 2006-09-13
DE122007000034I1 (de) 2007-08-09
ES2270822T3 (es) 2007-04-16
SI1165126T1 (sl) 2006-12-31
US6245568B1 (en) 2001-06-12
NL300269I1 (nl) 2007-05-01
CY2007008I1 (el) 2009-11-04
DE122007000033I1 (de) 2007-08-09
CY2007010I1 (el) 2009-11-04
KR20020013516A (ko) 2002-02-20
AU3909300A (en) 2000-10-16
PT1165126E (pt) 2006-12-29
LU91327I9 (fr) 2019-03-01
EP1165126A1 (fr) 2002-01-02
CA2368391A1 (fr) 2000-10-05
CA2368391C (fr) 2011-06-07
LU91328I9 (fr) 2019-03-01
FR07C0026I2 (fr) 2012-08-03
CY2007009I1 (el) 2010-07-28
LU91326I9 (fr) 2018-12-31
LTPA2007002I1 (lt) 2020-03-25
DE122007000032I1 (de) 2007-08-09
US20010021385A1 (en) 2001-09-13
DE60030698T2 (de) 2007-07-19
AR023166A1 (es) 2002-09-04
AU778937B2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
IL158107A0 (en) Human papillomaviruses vaccine
DZ2462A1 (fr) Vaccin antigrippal.
DK1023904T3 (da) Adjuvanser til anvendelse i vacciner
DZ3219A1 (fr) Vaccin
PL392363A1 (pl) Kompozycja szczepionki
IL150961A0 (en) Human immunodeficiency virus vaccine
DZ2283A1 (fr) Composition de vaccin.
IL189736A0 (en) Vaccine adjuvants
EP1389043A4 (fr) Vaccin contre le virus de la maladie de la fievre aphteuse
GB9915204D0 (en) Vaccine
HUP0202770A3 (en) Human papilloma virus vaccine
IS2797B (is) Bóluefni gegn ISA-veiru
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
GB9906437D0 (en) Vaccine
DE60015634D1 (de) Krankenliege
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
NO20002213L (no) Babesia vaksine
GB9909072D0 (en) Vaccine
FR2730936B1 (fr) Vaccin presentant une immunogenicite accrue
ITMI992410A0 (it) Vaccino per hiv
GB9917981D0 (en) Viral vaccine
GB9911824D0 (en) New vaccine formulations